FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer

Table 1 Studies evaluating the predictive roles of early 18F-fluorodeoxyglucose measured by positron emission tomography assessment on clinical outcome in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors

Ref.	EGFR-TKIs	Patient no.	Evaluation timing	EGFR mutation status			Significant association
				Mutant	Wild-type	Unknown	PFS or TTP1	OS
Takahashi et al[25]	Gefitinib	20	2 d	12	3	5	Yes	NA
Soto Parra et al[24]	Erlotinib	23	2 d	NA	NA	NA	Yes	No
Mileshkin et al[23]	Erlotinib	51	2 wk	4	30	17	Yes	Yes
Zander et al[26]	Erlotinib	34	1 wk	4	24	6	Yes	Yes
Benz et al[22]	Erlotinib	22	2 wk	4	1	17	Yes1	Yes
Bengtsson et al[21]	Erlotinib	125	2 wk	10	90	25	NA	Yes

¹Significant association with time to progression. NA: Data not available; EGFR-TKIs: Epidermal growth factor receptor-tyrosine kinase inhibitors; PFS: Progression-free survival; OS: Overall survival; TTP: Time to progression.